Ralph Zinner

5.9k citations

161 papers · 4.0k indexed · h-index 32

Impact in

Oncology top 1%
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- HER2/EGFR in Cancer Research
Cancer Research top 2%
- Cancer Genomics and Diagnostics

Papers in

Oncology 106
- Lung Cancer Research Studies 37
- Colorectal Cancer Treatments and Studies 25
- Cancer Treatment and Pharmacology 14
Pulmonary and Respiratory Medicine 91
- Lung Cancer Treatments and Mutations 66
- Lung Cancer Diagnosis and Treatment 32

Co-authors: David S. Hong Filip Jankú Apostolia M. Tsimberidou Siqing Fu Jennifer J. Wheler Aung Naing Sarina A. Piha‐Paul Razelle Kurzrock
Journals: Journal of Clinical Oncology (43 papers)Journal of Thoracic Oncology (9 papers)Oncotarget (9 papers)Investigational New Drugs (8 papers)Clinical Cancer Research (7 papers)
Partner nations: United States Netherlands Taiwan

In The Last Decade

Ralph Zinner

155 papers receiving 3.9k citations

Peers

Countries citing papers authored by Ralph Zinner

Since Specialization

Citations

This map shows the geographic impact of Ralph Zinner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ralph Zinner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ralph Zinner more than expected).

Fields of papers citing papers by Ralph Zinner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ralph Zinner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ralph Zinner. The network helps show where Ralph Zinner may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Ralph Zinner, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Ralph Zinner Line = papers co-authored together Ralph Zinner links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Designing Survey-Based Mobile Interfaces for Rural Patients With Cancer Using Apple’s ResearchKit and CareKit: Usability Study JMIR Formative Research ·Neul-Bom Yoon, Sabine Kirfel, Rong Wang, Ming‐Yuan Chih, Reema Patel, Ralph Zinner, Eliah Aronoff‐Spencer, 张祖忻	2024	0
2	L858R / L718Q and L858R / L792H Mutations of EGFR Inducing Resistance Against Osimertinib by Forming Additional Hydrogen Bonds Proteins Structure Function and Bioinformatics ·Yassa Dq, Samson Zegeye, Xiaoqi Liu, Sally R. Ellingson, Christine F. Brainson, Hunter Moseley, Ralph Zinner, Shulin Zhang, Qing Shao	2024	1
3	OA07.03 A Phase II Study of Frontline Rucaparib + Nivolumab in Platinum Sensitive ES SCLC: Interim Analysis Journal of Thoracic Oncology ·Aman Chauhan, Jill Kolesar, Donglin Yan, Andi Nurbaethy, S Irwandi, R.C. McGarry, J. Philip Miller, Aman Khurana, Habil. Maria Bordás, Y., Goetz Kloecker, D Rothman, Valentina Brusca, Timothy W. Mullett, 幸弘岩崎, Lowell Anthony, Ralph Zinner, Susanne M. Arnold	2021	4
4	Dose‐escalation study of vemurafenib with sorafenib or crizotinib in patients with BRAF‐mutated advanced cancers Cancer ·Filip Jankú, Divya Sakamuri, Shumei Kato, Helen J. Huang, E. Decuypere, Aung Naing, Veronica R. Holley, Sapna P. Patel, Rodabe N. Amaria, Gerald S. Falchook, Sarina A. Piha‐Paul, Ralph Zinner, Apostolia M. Tsimberidou, David S. Hong, Funda Meric‐Bernstam	2020	9
5	A Phase I Trial of the VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers Clinical Cancer Research ·Razelle Kurzrock, Douglas W. Ball, Marianna Zahurak, Barry D. Nelkin, Vivek Subbiah, Mariana Maria Pereira Cintra Farias Carvalho, Ashley O’Connor, Hazid Muslichin, Rose Parkinson, Justin A. Bishop, 健菊沢, Rajni Sharma, Christopher D. Gocke, Ralph Zinner, Michelle A. Rudek, Steven I. Sherman, Nilofer S. Azad	2019	19
6	Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors Scientific Reports ·І. О. Менейлюк, Roman Groisberg, Ken Hess, Siqing Fu, Jennifer J. Wheler, David S. Hong, Filip Jankú, Ralph Zinner, Sarina A. Piha‐Paul, Vinod Ravi, Robert S. Benjamin, Shreyaskumar Patel, Neeta Somaiah, Cynthia E. Herzog, Daniel D. Karp, Jason Roszik, Funda Meric‐Bernstam, Vivek Subbiah	2017	21
7	TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics Molecular Cancer Therapeutics ·Jennifer J. Wheler, Filip Jankú, Aung Naing, Yali Li, Bettzy Stephen, Ralph Zinner, Vivek Subbiah, Siqing Fu, Daniel D. Karp, Gerald S. Falchook, Apostolia M. Tsimberidou, Sarina A. Piha‐Paul, Roosevelt Anderson, Daniele Cristina Oliveira, Vincent A. Miller, Roman Yelensky, J. Jack Lee, David S. Hong, Razelle Kurzrock	2016	73
8	Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study Cancer Research ·Jennifer J. Wheler, Filip Jankú, Aung Naing, Yali Li, Bettzy Stephen, Ralph Zinner, Vivek Subbiah, Siqing Fu, Daniel D. Karp, Gerald S. Falchook, Apostolia M. Tsimberidou, Sarina A. Piha‐Paul, Roosevelt Anderson, Daniele Cristina Oliveira, Vincent A. Miller, Roman Yelensky, J. Jack Lee, David S. Hong, Razelle Kurzrock	2016	149
9	Phase I study of azacitidine and oxaliplatin in patients with advanced cancers that have relapsed or are refractory to any platinum therapy Clinical Epigenetics ·Apostolia M. Tsimberidou, Rabih Said, Kirk S. Culotta, Ignacio I. Wistuba, Jaroslav Jelı́nek, Siqing Fu, Gerald S. Falchook, Aung Naing, Sarina A. Piha‐Paul, Ralph Zinner, Zahid H. Siddik, Guangan He, Kenneth R. Hess, David J. Stewart, Razelle Kurzrock, Jean‐Pierre J. Issa	2015	14
10	Triple-Negative Breast Cancer Patients Treated at MD Anderson Cancer Center in Phase I Trials: Improved Outcomes with Combination Chemotherapy and Targeted Agents Molecular Cancer Therapeutics ·Prasanth Ganesan, Stacy L. Moulder, J. Jack Lee, Filip Jankú, Vicente Valero, Ralph Zinner, Aung Naing, Siqing Fu, Apostolia M. Tsimberidou, David S. Hong, Bettzy Stephen, Philip Stephens, Roman Yelensky, Funda Meric‐Bernstam, Razelle Kurzrock, Jennifer J. Wheler	2014	29
11	Analysis of 1,115 Patients Tested for MET Amplification and Therapy Response in the MD Anderson Phase I Clinic Clinical Cancer Research ·Denis L. Jardim, Chad Tang, Débora De Melo Gagliato, Gerald S. Falchook, Kenneth R. Hess, Filip Jankú, Siqing Fu, Jennifer J. Wheler, Ralph Zinner, Aung Naing, Apostolia M. Tsimberidou, B.B. Bock, Andrew Hansche, Sinchita Roy‐Chowdhuri, Raja Luthra, Ravi Salgia, Razelle Kurzrock, Funda Meric‐Bernstam, David S. Hong	2014	65
12	Synergy Between VEGF/VEGFR Inhibitors and Chemotherapy Agents in the Phase I Clinic Clinical Cancer Research ·Chad Tang, Kenneth R. Hess, Denis L. Jardim, Débora De Melo Gagliato, Apostolia M. Tsimberidou, Gerald S. Falchook, Siqing Fu, Filip Jankú, Aung Naing, Sarina A. Piha‐Paul, Vivek Subbiah, Jennifer J. Wheler, Ralph Zinner, Razelle Kurzrock, Lee M. Ellis, Gonzalo Martín D'Avola, David S. Hong	2014	11
13	Predicting High‐Throughput Screening Results With Scalable Literature‐Based Discovery Methods CPT Pharmacometrics & Systems Pharmacology ·Trevor Cohen, Dominic Widdows, Clifford Stephan, Ralph Zinner, André Nuber, Thomas C. Rindflesch, P.H. O'Connor Davies	2014	24
14	PRONOUNCE: Randomized, Open-Label, Phase III Study of First-Line Pemetrexed + Carboplatin Followed by Maintenance Pemetrexed versus Paclitaxel + Carboplatin + Bevacizumab Followed by Maintenance Bevacizumab in Patients ith Advanced Nonsquamous Non–Small-Cell Lung Cancer Journal of Thoracic Oncology ·Ralph Zinner, Coleman K. Obasaju, David R. Spigel, Robert Weaver, J. Thaddeus Beck, David Waterhouse, Manuel Modiano, Borys Hrinczenko, Petros Nikolinakos, Jingyi Liu, Andrew Koustenis, Katherine B. Winfree, Symantha Melemed, Susan C. Guba, Waldo Ortuzar, D. Desaiah, Joseph Treat, Ramaswamy Govindan, Helen J. Ross	2014	120
15	A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancer Investigational New Drugs ·Gerald S. Falchook, Stacy L. Moulder, Aung Naing, Jennifer J. Wheler, David S. Hong, Sarina A. Piha‐Paul, Apostolia M. Tsimberidou, Siqing Fu, Ralph Zinner, Filip Jankú, Alkame Akgümüş, Francesco DiMaggio, حمادة محمد إبراهيم, Razelle Kurzrock	2014	11
16	Treatment Rationale and Study Design for a Randomized Trial of Pemetrexed/Carboplatin Followed by Maintenance Pemetrexed Versus Paclitaxel/Carboplatin/Bevacizumab Followed by Maintenance Bevacizumab in Patients With Advanced Non–Small-Cell Lung Cancer of Nonsquamous Histology Clinical Lung Cancer ·Ralph Zinner, Scott Saxman, Guangbin Peng, Matthew Monberg, Waldo Ortuzar	2010	13
17	Algorithmic guided screening of drug combinations of arbitrary size for activity against cancer cells Molecular Cancer Therapeutics ·Ralph Zinner, A.V. Eremin, Elmira Popova, Paul Damien, Andrei Y. Volgin, Juri G. Gelovani, Reuben Lotan, Hai T. Tran, Claudio Pisano, Gordon B. Mills, Denis Kambouchner, Waun Ki Hong, Scott M. Lippman, John H. Miller	2009	48
18	Gene-Based Therapy: Novel Approaches Journal of Thoracic Oncology ·Ralph Zinner	2009	1
19	A Phase I Evaluation of Oral CI-1033 in Combination with Paclitaxel and Carboplatin as First-Line Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer Journal of Thoracic Oncology ·Alberto Chiappori, Peter Ellis, John Hamm, Jacob D. Bitran, Irene Eiseman, Almira Chairunnisa Wahyutomo, Yingying Cai, Stephen C. Olson, Peter F. Lenehan, Ralph Zinner	2006	12
20	Clinical and pharmacokinetic study of TNP-470, an angiogenesis inhibitor, in combination with paclitaxel and carboplatin in patients with solid tumors Cancer Chemotherapy and Pharmacology ·Hai T. Tran, George R. Blumenschein, Charles Lu, Christina A. Meyers, Vali Papadimitrakopoulou, Frank V. Fossella, Ralph Zinner, Timothy Madden, Kangzi Khor, Vinay K. Puduvalli, Reginald F. Munden, Mylene T. Truong, Roy S. Herbst	2004	31

About Ralph Zinner

Ralph Zinner is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Otorhinolaryngology and Hepatology, having authored 161 papers that have together received 4.0k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (66 papers), Lung Cancer Research Studies (37 papers), Lung Cancer Diagnosis and Treatment (32 papers), Colorectal Cancer Treatments and Studies (25 papers), Cancer Genomics and Diagnostics (22 papers), PI3K/AKT/mTOR signaling in cancer (14 papers), Cancer Treatment and Pharmacology (14 papers) and Cancer therapeutics and mechanisms (11 papers). The work is most often cited by research in Oncology (2.0k citations), Cancer Research (771 citations), Pulmonary and Respiratory Medicine (1.5k citations), Otorhinolaryngology (123 citations) and Pathology and Forensic Medicine (463 citations). Ralph Zinner has collaborated with scholars based in United States, Netherlands and Taiwan. Frequent co-authors include David S. Hong, Filip Jankú, Apostolia M. Tsimberidou, Siqing Fu, Jennifer J. Wheler, Aung Naing, Sarina A. Piha‐Paul, Razelle Kurzrock, Gerald S. Falchook and Funda Meric‐Bernstam. Their work appears in journals such as Journal of Clinical Oncology, Journal of Thoracic Oncology, Oncotarget, Investigational New Drugs and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact